Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

[Soluble CD40 ligand: a potential marker of cardiovascular risk].

San Miguel Hernández A, Inglada-Galiana L, García Iglesias R, Alonso Castillejos N, Martín Gil FJ.

Rev Clin Esp. 2007 Sep;207(8):418-21. Spanish.

PMID:
17688874
2.

Soluble CD40 ligand in acute coronary syndromes.

Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML; CAPTURE Study Investigators.

N Engl J Med. 2003 Mar 20;348(12):1104-11.

3.

CD40 ligand--assessing risk instead of damage?

Freedman JE.

N Engl J Med. 2003 Mar 20;348(12):1163-5. No abstract available.

PMID:
12646674
4.

Inflammatory biomarkers of the patient with myocardial insufficiency.

Blake GJ.

Curr Opin Crit Care. 2003 Oct;9(5):369-74. Review.

PMID:
14508149
5.

Soluble CD40 ligand in acute coronary syndromes.

Kritharides L, Lau GT, Freedman B.

N Engl J Med. 2003 Jun 19;348(25):2575-7; author reply 2575-7. No abstract available.

6.

CD40 ligand: a novel target in the fight against cardiovascular disease.

Vishnevetsky D, Kiyanista VA, Gandhi PJ.

Ann Pharmacother. 2004 Sep;38(9):1500-8. Epub 2004 Jul 27. Review.

PMID:
15280513
7.

The CD40/CD40 ligand system: linking inflammation with atherothrombosis.

Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C.

J Am Coll Cardiol. 2009 Aug 18;54(8):669-77. doi: 10.1016/j.jacc.2009.03.076. Review.

8.

Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.

Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Frøland SS, Gullestad L.

Circulation. 1999 Aug 10;100(6):614-20.

9.

Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes.

Monroe VS, Kerensky RA, Rivera E, Smith KM, Pepine CJ.

J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):23S-30S. Review.

10.

Low molecular weight heparins in the cardiac catheterization laboratory.

Montalescot G, Cohen M.

J Thromb Thrombolysis. 1999 Jun;7(3):319-23. Review. No abstract available.

PMID:
10373715
12.

Circulating soluble CD40 ligand mediates the interaction between neutrophils and platelets in acute coronary syndrome.

Setianto BY, Hartopo AB, Gharini PP, Anggrahini DW, Irawan B.

Heart Vessels. 2010 Jul;25(4):282-7. doi: 10.1007/s00380-009-1199-1. Epub 2010 Jul 31.

PMID:
20676835
13.

The CD40-CD40L system in cardiovascular disease.

Pamukcu B, Lip GY, Snezhitskiy V, Shantsila E.

Ann Med. 2011 Aug;43(5):331-40. doi: 10.3109/07853890.2010.546362. Epub 2011 Jan 18. Review.

PMID:
21244217
14.

Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor.

Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K.

Am Heart J. 1995 Oct;130(4):877-92. Review.

PMID:
7572600
15.

[Fibrinogen. Cardiovascular risk factor or marker?].

Canseco-Avila LM, Jerjes-Sánchez C, Ortiz-López R, Rojas-Martínez A, Guzmán-Ramírez D.

Arch Cardiol Mex. 2006 Oct-Dec;76 Suppl 4:S158-72. Review. Spanish.

PMID:
17469344
16.
17.
18.

New antiplatelet agents.

White HD, French JK, Ellis CJ.

Aust N Z J Med. 1998 Aug;28(4):558-64.

PMID:
9777140
19.

[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].

Auer J, Berent R, Maurer E, Mayr H, Weber T, Eber B.

Herz. 2001 Mar;26(2):99-110. Review. German.

PMID:
11349620
20.

[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].

Fries R, Böhm M.

Med Klin (Munich). 2003 Jun 15;98(6):326-34. Review. German.

PMID:
12811417

Supplemental Content

Support Center